Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai, China.
Department of Endocrinology, Zhongshan Hospital of Fudan University, Shanghai, China.
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):379-391. doi: 10.1016/j.bbcan.2019.03.001. Epub 2019 Apr 2.
The mechanistic target of rapamycin (mTOR) pathway coordinates organismal growth and homeostasis in response to growth factors, nutrients, and cellular energy stage. The pathway regulates several major cellular processes and is implicated in various pathological conditions, including hepatocellular carcinoma (HCC). This review summarizes recent advances of the mTOR pathway, highlights the potential of the mTOR pathway as a therapeutic target, and explores clinical trials targeting the mTOR pathway in HCC. Although the review focuses on the mTOR pathway involved in HCC, more comprehensive discussions (eg, developing a rational design for future trials targeting the mTOR pathway) are also applicable to other tumors.
雷帕霉素靶蛋白（mTOR）通路通过响应生长因子、营养物质和细胞能量状态来协调机体生长和内稳态。该通路调节多种主要的细胞过程，与多种病理状况有关，包括肝细胞癌（HCC）。本综述总结了 mTOR 通路的最新进展，强调了 mTOR 通路作为治疗靶点的潜力，并探讨了 HCC 中靶向 mTOR 通路的临床试验。虽然本综述侧重于 HCC 中涉及的 mTOR 通路，但更全面的讨论（例如，为未来靶向 mTOR 通路的试验制定合理的设计）也适用于其他肿瘤。
